CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Launay et al compare the persistence of cross-neutralizing antibodies up to 3 months post-booster. The monovalent (MV) recombinant protein Beta-variant (MVB.1.351) vaccine induces higher and ...

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data update from ...

Ahmet Sezer, professor in the Department of Medical Oncology at Başkent University in Adana, Turkey and a trial investigator. Sezer said: "Libtayo has demonstrated an impressive level of ...